Selective androgen receptor modulators (SARMs) induce anabolic effects on muscle without the adverse effects of androgenic steroids. In this first-in-human study, we report the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of the SARM GSK2881078.
Introduction
One of the debilitating consequences of chronic illness is the impairment of physical function due to muscle wasting, which also often accompanies advanced age. Sarcopenia, defined as a marked loss of muscle mass and strength due to ageing, is associated with impaired physical function and higher rates of institutionalization, mortality and diminished quality of life [3] [4] [5] [6] [7] . Similarly, cachexia describes the accelerated loss of body weight, which often includes loss of muscle mass, that occurs in persons with acute or chronic illness including cancer, heart failure, chronic obstructive pulmonary disease, kidney disease, arthritis, burn injury and acquired immune deficiency syndrome [8] .
Physical therapy and exercise are the current standards of treatment for muscle wasting, and these have been shown to be effective for increasing muscle mass and improving physical function [9] . However, to date there is no medication approved by either the United States Food and Drug Administration (FDA) or the United Kingdom Medicines and Healthcare Products Regulatory Agency that can be used with the standard of care to treat sarcopenia or cachexia of any aetiology.
Testosterone has shown therapeutic efficacy, improving muscle mass and physical function, especially in conjunction with exercise [10, 11] . However, testosterone replacement therapy has been associated with significant side effects [12] [13] [14] [15] [16] . These include cardiovascular events, prostatic stimulation and enlargement, a possible increased risk of prostate cancer and elevated haemoglobin levels. Selective androgen receptor modulators (SARMs) have the potential to act selectively on the androgen receptor to produce anabolic effects on muscle, without adverse effects (AEs) on the prostate in men or androgenic effects in women, including hirsutism [17] [18] [19] .
SARMs bind to the androgen receptor and induce conformational changes that facilitate interactions with specific co-activator and co-repressor proteins [20, 21] . These interactions result in downstream regulation of target genes and other receptor-mediated pathways [11, 17, 18] . Induction of anabolic effects on muscle and bone, overall body metabolism and physical function could be useful for many clinical conditions in which subjects experience muscle wasting and impaired physical function. However, the development of a SARM with the balance of beneficial effects on muscle without AEs has proven difficult. SARMs currently in development include enobosarm [22, 23] , LGD-4033 [24] and GSK2881078. These SARM compounds, and MK-0773, which was discontinued [25] , have shown common pharmacodynamic (PD) changes associated with androgen receptor agonists: lowering of high-density lipoprotein (HDL), thyroxine-binding globulin (TBG) and sex hormonebinding globulin (SHBG); increased muscle mass; and positive effects on selected measures of physical function [19, [22] [23] [24] [25] . Only enobosarm was tested in a Phase III registration trial but it was not approved by the FDA.
The SARM GSK2881078 [(R)-1-(1-(methylsulfonyl) propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile, Chemical Abstracts Service registry number 1539314-06-1] shows greater than 100-fold selectivity for the androgen receptor over glucocorticoid, mineralocorticoid and progesterone receptors. GSK2881078 at 0.3 mg kg -1 day
dosed orally once daily (QD) for 28 days restored the weight of the levator ani muscle in orchiectomized rats to that of sham-operated rats but produced only a minor increase in prostate weight compared with vehicle-treated orchiectomized rats (unpublished data on file, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA, USA 19406).
This was the first study of GSK2881078 in humans, evaluating the safety, tolerability, pharmacokinetics (PK), and PD of the drug after oral administration of singleascending doses and repeat-ascending doses to healthy male and healthy postmenopausal female subjects. The purpose of this first-in-human study was to provide sufficient confidence in the human safety and PK characteristics of GSK2881078 to inform progression to further repeat-dose and proof-of-concept studies. The dose range proposed in this study was based on a low starting dose, using less than the minimum anticipated biological effect level (MABEL; see Supporting Information) derived from preclinical studies, including 13-week toxicology studies in rats. Subsequent dose escalation was done to show clear PD effects and explore supra-therapeutic exposures within the no observable AE level, if supported by adequate safety and tolerability at previous doses.
Methods

Study design
This two-part, randomized, double-blind [investigators and subjects blinded to treatment; sponsor (GlaxoSmithKline) unblinded for subject safety purposes] first-in-human, doseescalation, placebo-controlled study was designed to evaluate the safety, tolerability, PK and PD of the SARM GSK2881078 in single and repeat doses in healthy male subjects and healthy postmenopausal female subjects.
In Part A, a four-way crossover design, each subject (males only) received a single dose (D) of GSK2881078 at weekly intervals over 4 weeks (D1, 0.1 mg; D2, 0.2 mg; D3, 0 mg; D4, 0.05 mg) or matching placebo (P) in varying sequences (D1-D2-D3-P, D1-D2-P-D4, D1-P-D3-D4, or P-D2-D3-D4).
('P' designates intact blind, while '0 mg' dose denotes investigator unblinded. A 0-mg dose was given to evaluate clearance during one investigator-unblinded dosing period owing to measurable baseline GSK2881078 concentrations in subjects dosed in the previous dosing period. Subjects remained blinded.) On day À1, subjects reported for study assessments and a meal. Following an overnight fast (≥8 h), subjects were dosed on day 1, then assessed over a 24-h period prior to discharge the next day to continue a 6-day washout period before returning for the next dose. Dose selection for Part B was based, in part, on data from Part A.
In Part B, each subject received repeat administration of study drug over 7 days (placebo or 0.05 mg GSK2881078) or over 14 days. Males and females were included in Part B, with male dosing cohort data reviewed prior to females being dosed. In consideration of the long half-life (t 1/2 ) observed in Part A, a loading regimen [twice daily (BID) dosing] was used to approximate steady-state exposures during 14 days of dosing (for males: placebo or GSK2881078 0.2 mg BID days 1-3, then 0.08 mg QD days 4-14, 0.24 mg BID days 1-3, then 0.24 mg QD days 4-14, 0.48 mg BID days 1-3, then 0.48 mg QD days 4-14, or 0.75 mg BID days 1-3, then 0.75 mg QD days 4-14; for females: placebo or GSK2881078 0.24 mg BID days 1-3, then 0.24 mg QD days 4-14; or 0.35 mg BID days 1-3, then 0.35 mg QD days [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The BID loading dose was given on days 1-3 at 08:00 h and 18:00 h, with subsequent single doses given at 08:00 h. On day À1, subjects reported for study assessments and a meal, followed by an overnight fast and dosing on the morning of day 1. Postdose, subjects underwent safety and PK assessments. In the group of subjects that received 0.24 mg doses, dosing on day 12 was under fed conditions (subjects received a standard meal 30 min prior to dosing) to provide exposure comparison to fasted conditions (day 14). All subjects remained at the study sites for the duration of the study. The last follow-up visit was at approximately day 42.
The investigators and sponsor complied with all regulatory requirements relating to safety reporting to regulatory authorities, institutional review boards (IRBs) and investigators. The study protocol was approved by independent IRBs at the respective study sites. [ 
Assessments
For the primary objective of assessing safety and tolerability, clinical laboratory tests, vital signs, ECGs, physical examinations, echocardiograms, cardiac biomarkers and cardiac telemetry were conducted, and AEs were monitored.
For the secondary objective of examining the PK profile of GSK2881078, plasma samples were collected and assayed using a validated analytical method based on protein precipitation, followed by high-performance liquid chromatography/mass spectrometry/mass spectrometry (HPLC-MS/MS) analysis. Quality control (QC) samples, prepared at three different analyte concentrations and stored with study samples, were analysed with each batch of samples against separately prepared calibration standards. For the analysis to be acceptable, no more than one-third of the QC results were to deviate from the nominal concentration by more than 15%, and at least 50% of the results from each QC concentration were to be within 15% of nominal.
PK analyses of the concentration-time data for plasma GSK2881078 were conducted using noncompartmental Model 200 (for extravascular administration) Phoenix Build 6.3.0.395, WinNonlin 6.3 (Pharsight Corporation, St Louis, MO, USA). Actual elapsed time from dosing was used to estimate all individual plasma PK parameters for evaluable subjects. The maximum observed concentration (C max ) and the time at which C max was observed (T max ) were determined directly from the raw concentration-time data. The area under the plasma concentration-time curve over the dosing interval (AUC (0-τ) ) and the area under the plasma concentration-time curve from time zero to the last quantifiable time point (AUC (0-t) ) were calculated by a combination of linear and logarithmic trapezoidal methods. The linear trapezoidal method was used for all incremental trapezoids arising from increasing concentrations, and the logarithmic trapezoidal method was used for those arising 
BID, twice daily; QD, once daily; SD standard deviation from decreasing concentrations. In addition, the predose (trough) concentration (C τ ) was determined, where τ is the end of dosing interval. Fasting blood samples for biomarker assessment were drawn in the Part B predose baseline and during treatment to detect levels of hormones [serum luteinizing hormone (LH), SHBG, follicle-stimulating hormone (FSH), prolactin, inhibin B, oestradiol, progesterone, testosterone and dihydrotestosterone (DHT)] and for lipid panels [plasma total cholesterol, low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), HDL, triglycerides and serum apolipoproteins A1 and B (ApoA1 and ApoB)]. An ad hoc calculation and summary of free testosterone [26] was also conducted for subjects in the 14-day treatment regimens.
Fasting samples were drawn in Parts A and B to assess cardiovascular biomarkers [plasma brain natriuretic peptide (BNP) and troponin]. Biomarkers assessed only in Part B were adrenal [plasma adrenocorticotropic hormone (ACTH), serum cortisol and dehydroepiandrosterone sulphate] and metabolic [serum insulin-like growth-factor-1, insulin-like growth factor-binding protein 3, thyroxine (T4), free T4 and thyroid-stimulating hormone] and plasma fasting insulin and glucose.
Statistical analyses
The sample size for each cohort was based on feasibility; no formal power/sample size calculations were performed, and no formal statistical hypotheses were tested. Version 9.1 or higher of the SAS system (Cary, NC, USA) was used to analyse the data. For Part B 14-day repeat-dose cohorts, placebo subjects were combined across cohorts for summarization and statistical analysis. Part B results are reported by gender. Safety data were summarized using the population of subjects who received at least one dose of study drug. Biomarker analyses were conducted on subjects in the safety population who had biomarker assessments at baseline and at least one postbaseline assessment. PK data were analysed for the subjects in the safety population for whom a PK sample was obtained and analysed.
For Part B of the study, change from baseline biomarker, lipid and hormone values were analysed separately in male and female subjects using analysis of covariance, with baseline covariates. Dose proportionality of C max and AUC (0-τ) on day 14 in males following QD administration of GSK2881078 was analysed using appropriate power and analysis of variance (ANOVA) models. Achievement of steady-state exposure was assessed visually and from the estimate of the slope from the linear regression of log C τ vs. time on days 4-8. The effect of food on GSK2881078 PK parameters was assessed by comparing day 12 (fed) to day 14 (fasted) PK parameters (C max and AUC (0-τ) ) following administration of 0.24 mg GSK2881078 QD to males, using ANOVA. PK parameters were natural log-transformed prior to statistical analysis.
Results
Subjects
A total of 99 subjects were enrolled. Treatments and subject demographics for Parts A and B are summarized in Table 1 .
All subjects enrolled in Part A completed the study. Four of the 89 subjects in Part B withdrew from treatment, three of them because of AEs.
PK
Plasma concentrations of GSK2881078 over time exhibited an initial rapid absorption phase following single and repeated administration (Figure 1 ). Plasma PK parameter estimates for Part A are summarized in Table 2 . A dose proportional increase was observed in geometric mean C max . Median t max was comparable across doses. The geometric mean t 1/2 was long (>100 h) and similar across all treatments. Here, the quantifiable concentrations after administration of placebo or 0 mg GSK2881078 were included in the analysis for the preceding treatment dose to better characterize GSK2881078 elimination.
Plasma PK parameters for Part B are summarized in Table 3 for male and female subjects. The median t max was similar across treatments and days, and no differences were observed Figure 1 Plasma concentration over (A) the first 24-h period following the last dose in Part B, and (B) the full 14-day period following the final dose in Part B. QD, once daily SARM GSK2881078: PK, PD, and safety in healthy men and women between genders (males: 1.00-2.00 h; females: 1.26-1.50 h). Unscheduled plasma samples were taken following the last dose better to characterize GSK2881078 elimination. Consequently, the time of the last measurable concentration (t last ) after the last dose was not consistent (ranging from 48-822 h in males and 671-746 h in females), resulting in higher intersubject variability for AUC (0-t) both in males and females on days 7-9 and day 14 [coefficient of variability (CVb) ranging from 59-99% in males and 31-59% in females] compared with days 1 and 12 (CVb ranging from 18-33% in males and 11-22% in females).
In males and females, the geometric means for AUC (0-τ) and C max differed by less than 20% at a comparable dose (0.24 mg). Intersubject variability for AUC (0-τ) and C max was similar in males and females, and typically within the range of 12-34%. The t 1/2 s were long (geometric means >100 h) and similar on days 7-9 and day 14 across all treatments in males. In females, the geometric mean t 1/2 at a comparable dose (0.24 mg) appeared 38% longer than in males. It is likely that this was attributable to the differences in t last , which was 340 h for four of the nine males compared with >620 h in all other instances.
The urine PK parameters of renal clearance (CLR) and percentage dose excretion at 24 h (fe24) were comparable between males and females [geometric mean CLR (ml h 
PD and biomarkers
Analysis of reproductive hormones in male subjects showed reductions in testosterone, DHT, and SHBG relative to baseline and placebo at all active doses ( Table 4 ). The reductions in testosterone at the two highest doses continued for 14 days after cessation of GSK2881078 treatment and were increasing toward baseline by follow-up day 28 at the lower doses and in all doses by follow-up day 42 (Figure 2 ). SHBG levels were stable or increasing by follow-up day 28 for all doses and, with the exception of the lowest dose (0.2 mg BID then 0.08 mg QD), had not yet returned to baseline by follow-up day 42 ( Figure 3 ). Adjusted mean changes from baseline on day 14 showed no apparent dose response in DHT or testosterone but there appeared to be a dose-response relationship for SHBG lowering (Table 4 and Figure 3 ). There was no apparent effect of treatment on calculated free testosterone ( Figure 4 ). Reductions in FSH were also observed at all doses but with no apparent dose-response relationship. There was no consistent reduction in LH with treatment. There were no clinically meaningful changes in oestradiol, inhibin, progesterone or prolactin in male subjects. In female subjects, SHBG was reduced in a dosedependent manner (Table 5) . SHBG levels remained suppressed on follow-up day 28, and although levels started to increase by follow-up day 42, they had still not returned to baseline (Figure 3 ). There were no other clinically meaningful changes in female reproductive hormones.
HDL, ApoA1, triglycerides and VLDL were reduced with GSK2881078 treatment relative to baseline and placebo both in males and females (Tables 4 and 5 ). No changes were observed for total cholesterol, LDL or total ApoB. In both males and females, HDL levels were returning to baseline by the end of the study ( Figure 5 ).
There was no consistent effect on adrenal biomarkers in male subjects. An increase in ACTH and cortisol was observed in the male 0.48-mg group on day 8. However, this effect was 
SARM GSK2881078: PK, PD, and safety in healthy men and women not observed at a higher dose and did not persist on day 14 (Table 4 ). This isolated increase in men was not considered clinically meaningful because cortisol levels remained within the normal range, and a dose-response relationship was not observed. ACTH and cortisol elevations decreased with continued dosing beyond day 8 and this was not associated with other clinical or safety signals. No clinically meaningful changes in adrenal hormones were observed in women (Table 5) . For metabolic biomarkers, TBG was reduced at all doses both in males and females. In addition, free T4 was increased at the high doses in males (0.48 mg and 0.75 mg) and females (0.35 mg) (Tables 4 and 5 ) without clinical effect. Specifically, there was no increase in heart rate and no tachycardia or other clinical symptoms. There were no clinically meaningful changes in other assessed metabolic biomarkers. Levels of the cardiac biomarker BNP were unaffected in male and female subjects over 14 days of dosing. All troponin levels were in the normal range, with the exception of one result on day 4 for a subject in the 0.48-mg group; repeat samples for troponin were normal and ECGs were unremarkable.
Safety
Overall, treatment was well tolerated. In Part A, two subjects (20%) had a single AE, one with extremity pain and one with an upper respiratory tract infection, both of which were mild. In Part B, 48 subjects (54%) had at least one AE. The most commonly reported AEs overall were: headache and upper respiratory tract infection (eight subjects, 9%); medical device site reaction (five subjects, 6%); and constipation, dyspepsia, and palpitations (each reported in three subjects, 3% each). The most common AEs (occurring in two or more subjects) considered related to the study drug were constipation, dyspepsia and nausea. In Part B, three subjects withdrew owing to AEs. A female subject on placebo developed chest pain on day 12. She was evaluated with an exercise stress test, which was abnormal (both events were serious AEs). She had emergency cardiac catheterization, which was unremarkable, and was followed without further dosing. A female subject on active treatment developed a maculopapular rash on day 10, and a skin biopsy was consistent with a drug reaction. She was discontinued from further dosing and treated with topical corticosteroids with resolution of the rash. She also had elevated alanine aminotransferase (ALT) to 2.9 × upper limit of normal (ULN) with no increase in bilirubin. In addition, a male on active treatment developed a shortened QT interval after his first dose and withdrew from the study. This ECG finding was not considered to be drug related. A female on active treatment developed atopic dermatitis, not considered drug related, toward the end of her dosing period, and also had an elevation of ALT to 2.3 × ULN, with no increase in bilirubin. Two men on active treatment experienced muscle soreness after demanding physical activity in the follow-up period, 14 and 28 days, respectively, after the last dose. Both men showed marked elevation of creatine phosphokinase (CPK) ( Table 4 ANCOVA results for change from baseline in selected lipids, adrenal and metabolic hormone biomarkers in males SARM GSK2881078: PK, PD, and safety in healthy men and women Table 4 (Continued) ANCOVA, analysis of covariance; ACTH, adrenocorticotropic hormone; CI, confidence interval; DHT, dihydrotestosterone; FSH, follicle-stimulating hormone; HDL, high-density lipoprotein; IGF-1, insulin-like growth factor-1; IGF-3, insulin-like growth factor-3; NA, not applicable; SHBG, sex hormone-binding globulin; TBG, thyroxine-binding globulin; VLDL, very-low-density lipoprotein a For between treatment comparisons to be reported, the sample size in each treatment group involved in the comparison must have been at least three.
considered severe but not drug related. No other subjects showed elevation of ALT ≥2 × ULN during treatment.
Discussion
Investigations into SARM compounds at various stages of preclinical and clinical development are ongoing. These agents could address deleterious muscle wasting phenomena that occur with advanced age and chronic disease [22] [23] [24] [25] 27] . The current study was a randomized, double-blind, placebocontrolled investigation of the safety, tolerability, PK and PD of GSK2881078, a novel SARM compound, in single and repeat doses in healthy male and postmenopausal female subjects.
Overall, the dose range of GSK2881078 evaluated was well tolerated among a sample of healthy male and postmenopausal female subjects. AEs occurred in half the study population, with a similar distribution between active treatment and placebo groups. Although SARMs and oral androgens are associated with elevations in liver enzymes [25] , no clinically significant hepatic signals were observed.
There was an approximate dose-proportional increase in exposures of GSK2881078 in the dose range evaluated in this study. Food did not significantly alter AUC (0-τ) but was associated with a 21% decrease in C max . Less than 2% of the GSK2881078 dose was excreted in urine, and CLR was similar in males and females. While trough concentrations were used to assess steady-state attainment in the study, with an observed t 1/2 in humans that was much longer than anticipated, the collection of trough samples only on days 4-8 limited an adequate assessment of steady-state attainment. With an estimated t 1/2 >100 h, steady-state is expected to be achieved much later than day 8. The long t 1/2 probably also accounted for the measurable concentrations in subjects while receiving 0 mg GSK2881078 preceded by an active dosing regimen 5 days earlier in Part A. A washout period longer than 5 days is needed in future studies of this molecule. Given the long t 1/2 of GSK2881078 and the objective of emulating steady-state exposure profiles over the 14-day course of the study, a loading regimen was devised based on the Part A data, which would elevate plasma exposures rapidly and maintain them over the study period. As a result, direct comparison of PK results to address accumulation of GSK2881078 from day 1 to day 14 is not possible using standard PK approaches but will be addressed in future analyses making use of population PK modelling.
Following repeat dosing, there was an apparent 38% difference in t 1/2 between genders for the 0.24 mg BID then 0.24 mg QD treatment, which was probably attributable to t last occurring much earlier for some of the male subjects. As the quantifiable concentrations with placebo or 0 mg GSK2881078 following single-dose administration in Part A were included in the analysis for the preceding treatment dose to better characterize GSK2881078 elimination, t last exceeded the last scheduled sampling time for the corresponding treatment, accounting for the high variability of AUC (0-t) (CVb ranging from 43% to 96%) and the apparent lack of dose proportionality in contrast to Part B, where additional samples permitted improved characterization of the long t 1/2 .
Consistent with other oral androgens and other SARMs under investigation, GSK2881078 (doses of 0.2 mg BID then 0.08 mg QD and higher) was associated with reductions in HDL, ApoA1, triglycerides and VLDL relative to baseline and placebo in male and female subjects [22, 24] . This was an expected result because androgen receptor agonists are known to affect hepatic metabolism. There were no apparent changes in total cholesterol, LDL or ApoB. The clinical implications of androgen-associated lipid alterations are not clear.
Reductions in testosterone, DHT, SHBG and FSH were observed relative to baseline and placebo in male subjects, and reductions in SHBG in female subjects receiving GSK2881078. The accompanying decrease in SHBG in both males and females is consistent with hepatic effects observed with other SARMs [22, 25] . Free testosterone did not change in either males or females, consistent with the decrease in SHBG. No clinically meaningful changes were observed in other reproductive hormones. Androgen receptor agonists can act centrally on the hypothalamicpituitary-gonadal axis, to suppress the signals for gonadal hormonal secretion, LH and FSH. In the present study, neither free testosterone nor LH levels declined, suggesting that the decrease in total testosterone was not due to hypothalamic inhibition. Thus, in men, total testosterone levels can fall, as observed. Effects in the postmenopausal women were minimal. In addition, androgen receptor agonists also suppress production of binding globulins such as SHBG in the liver, leading to lower levels of endogenous Figure 2 Mean (SE) total testosterone up to 42 days in male subjects with 14-day treatment. BID, twice daily; QD, once daily; SE, standard error sex steroids (testosterone and oestradiol), typically without significant effect on free hormone levels. All hormonal levels were returning to baseline values by the end of the study.
There were no consistent, clinically meaningful changes in adrenal hormones in the male or female subjects. In male and female subjects, TBG was reduced relative to baseline and placebo. As noted, androgen receptor agonists act on the liver to reduce the levels of binding globulins, such as TBG and SHBG. Free hormone levels typically are unaffected, although here, men and women alike showed increases in free T4 at the higher doses. The clinical significance of this Figure 3 Mean (SE) SHBG up to 42 days in male and female subjects with 14-day treatment. BID, twice daily; QD, once daily; SE, standard error; SHBG, sex hormone-binding globulin Figure 4 Mean (SE) free testosterone up to 14 days in male subjects with 14-day treatment. Free testosterone was estimated by calculation [26] . BID, twice daily; QD, once daily; SE, standard error SARM GSK2881078: PK, PD, and safety in healthy men and women is unclear, although there was no evidence of a clinical response to this, such as an increased heart rate. There were no clinically meaningful changes in any other metabolic biomarkers. Monitoring of BNP and troponin showed no evidence of myocardial injury.
Comparison of our results with those from longer duration studies of other SARMs in development (enobosarm [22] and LGD-4033 [24] ) reveals modest differences. Our high-dose male cohort (0.75 mg) yielded approximately similar levels of SHBG and total testosterone suppression as those seen in high-dose cohorts of enobosarm and LGD-4033, suggesting similar levels of androgen receptor agonism. Adverse effects were generally not different between SARMs. Of note were elevations in ALT seen with enobosarm, leading to study discontinuation in one subject receiving the highest dose examined, 3 mg QD. One possible differentiating feature of GSK2881078 is the long t 1/2 of the compound. GSK2881078 has a terminal t 1/2 of 7.5 days, considerably longer than enobosarm (22 h [28] ) or LGD (24-36 h [24] ), which may limit peak : trough compound excursion. While daily testosterone concentrations are diurnal [29] , a more static exposure may offer more sustained anabolic stimulation of muscle.
Currently, there are no approved therapies for the prevention or treatment of deleterious muscle wasting, although there is a clinical need for safe anabolic compounds such as SARMs. GSK2881078 has demonstrated clear target engagement shown by significant reductions in SHBG, TBG and HDL. Good safety and tolerability were also demonstrated and are consistent with the broad safety margin shown in preclinical toxicology studies (unpublished data on file, GlaxoSmithKline, King of Prussia, PA, USA). These data, combined with the doseproportional plasma levels and predictable biomarker profiles of GSK2881078, provide a pharmacological rationale for further clinical study of this novel SARM for the treatment of muscle wasting. 
